Hypothesis

Transient mitochondrial reactive oxygen species (ROS) bursts, such as those elicited by a controlled inflammatory stimulus, lower the apoptotic threshold of senolytic‑resistant senescent cells by oxidizing critical cysteine residues on BCL‑2 family proteins, thereby sensitizing them to BCL‑2 inhibitors like navitoclax (ABT263) or ARV825.

Mechanistic Rationale

• Senolytics rely on inducing mitochondrial outer membrane permeabilization (MOMP) through BCL‑2/BCl‑xL inhibition.
• A subset of senescent cells resists this due to heightened mitochondrial quality control and antioxidant capacity 2.
• Inflammatory challenges (e.g., low‑dose LPS) provoke a rapid, mitochondrial ROS surge that can oxidize BCL‑2 and MCL‑1, reducing their anti‑apoptotic affinity 4.
• This oxidative modification mirrors the effect of senosensitizers described in preclinical work, but leverages the endogenous danger signal rather than exogenous chemicals 1.

Experimental Design

1. Mouse model: Use aged (20‑month) C57BL/6 mice bearing inducible p16‑3MR reporter to track senescent cells.
2. Groups (n=8 per group):
   • Vehicle control
   • Senolytic alone (navitoclax 50 mg/kg, oral, weekly ×3)
   • Inflammatory priming alone (LPS 0.1 mg/kg i.p., 24 h before senolytic)
   • Combined priming + senolytic (same schedule)
   • ROS scavenger control (N‑acetylcysteine 150 mg/kg i.p. with priming + senolytic) to test ROS dependence.
3. Readouts (48 h after final senolytic dose):
   • Flow cytometry of p16‑3MR‑positive cells in spleen, liver, kidney, adipose.
   • Plasma SASP cytokines (IL‑6, CCL2) via Luminex.
   • Platelet counts and bleeding time to assess thrombocytopenia.
   • Mitochondrial ROS measured by MitoSOX in isolated senescent cells.

Predicted Outcomes

• Primary: Combined priming + senolytic will achieve >80 % reduction of p16‑positive cells in tissues, surpassing the 30‑70 % range seen with senolytics alone 2.
• Secondary: SASP factor reduction will be proportionally greater than cell loss, indicating selective removal of the most inflammatory senescent cells.
• Safety: Platelet counts will remain >150 ×10⁹/L in the combined group, comparable to senolytic‑alone, indicating that ROS priming does not exacerbate navitoclax‑induced thrombocytopenia.
• Control: NAC co‑treatment will abolish the enhanced clearance, confirming ROS mediation.

Potential Caveats and Falsifiability

• If priming does not increase clearance beyond senolytic alone, the hypothesis is falsified.
• If NAC does not blunt the effect, alternative mechanisms (e.g., NF‑κB signaling) must be considered.
• Excessive ROS could cause off‑target toxicity; dose‑finding pilots are required.

This hypothesis translates the observed infection‑reactivable senescent cell pool into a therapeutic opportunity: by harnessing a brief, endogenous mitochondrial ROS burst, we can convert resistant senescent cells into senolytically sensitive targets, improving systemic efficacy while preserving the safety window of current senolytics.